Pancreatic Cell News Volume 4.05 | Feb 12 2013

    0
    35

    Pancreatic Cell News 4.05 February 12, 2013

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs 
    Cell Therapy News on Facebook  Pancreatic Cell News on Twitter

    TOP STORY
    Sirtuin 3 Regulates Mouse Pancreatic Beta Cell Function and Is Suppressed in Pancreatic Islets Isolated from Human Type 2 Diabetic Patients
    Investigators analyzed changes in sirtuin 3 (SIRT3) expression in experimental models of type 2 diabetes and in human islets isolated from type 2 diabetic patients. They also determined the effects of SIRT3 knockdown on beta cell function and mass in INS1 cells. [Diabetologia] Abstract

    STEMdiff™ Definitive Endoderm Kit - For Easy, Standardized hPSC Differentiation

    PUBLICATIONS (Ranked by impact factor of the journal)

    DIABETES

    Incretin-Stimulated Interaction between β-Cell Kv1.5 and Kvβ2 Channel Proteins Involves Acetylation/Deacetylation by CBP/SirT1
    The authors determined whether incretins modulate Kv1.5α/Kvβ2 interaction via post-translational modifications and the mechanisms involved. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) reduced apoptosis in INS-1 β-cells overexpressing Kv1.5, and RNAi-mediated knockdown of endogenous Kv1.5 attenuated apoptotic β-cell death. Further studies demonstrated that CREB binding protein (CBP)/Sirtuin deacetylase (SirT1) mediated acetylation/deacetylation and interaction between Kvβ2 and Kv1.5 in response to GIP/GLP-1. [Biochem J] Abstract

    Hypoglycemia Reduces VEGF-A Production by Pancreatic Beta Cells as a Regulator of Beta Cell Mass
    Scientists showed that secretion of vascular endothelial growth factor A (VEGF-A), but not VEGF-A gene transcription, in either cultured islets or purified pancreatic beta cells, was significantly reduced early on during low glucose conditions. [J Biol Chem] Abstract | Full Article

    Glucocorticoid-Induced Suppression of β-Cell Proliferation Is Mediated by Mig6
    Researchers hypothesized that dexamethasone impairs β-cell proliferation by increasing the expression of Mig6 and thereby decreasing downstream signaling of epidermal growth factor receptor. They found that Dex induced Mig6 and decreased [3H]thymidine incorporation, an index of cellular replication, in mouse, rat, and human islets. [Endocrinology] Abstract

    Adipose Tissue-Derived Mesenchymal Stem Cells Efficiently Differentiate into Insulin-Producing Cells in Pancreatic Islet Microenvironment Both In Vitro and In Vivo
    The differentiation of mesenchymal stem cells (MSCs) derived from rat tissues (adipose, rAT; bone marrow, rBM) were analyzed by in vitro and in vivo co-culture experiments. The insulin-producing capacities of islets transplanted under the renal kidney capsule with rAT- and rBM-MSCs were compared and the reduction of hyperglycemia symptoms in rat models was examined. [Cytotherapy] Abstract

    Liver-Derived Systemic Factors Drive β Cell Hyperplasia in Insulin-Resistant States
    To test the hypothesis that crosstalk between the liver and pancreatic islets modulates β cell growth in response to insulin resistance, investigators used the liver-specific insulin receptor knockout mouse, a unique model that exhibits dramatic islet hyperplasia. [Cell Rep] Full Article | Graphical Abstract

    PANCREATIC CANCER

    Enhancer of Zeste Homolog 2 Silences miR-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin
    The authors identified microRNAs (miRs) that are regulated by enhancer of zeste homolog 2 (EZH2) and studied their functions in pancreatic ductal adenocarcinoma (PDAC) cells. They performed miR profile analysis of PDAC cells incubated with EZH2 inhibitor DZnep, and pancreatic ductal epithelial cells that overexpressed EZH2. [Gastroenterology] Abstract

    Targeting Gemcitabine Containing Liposomes to CD44 Expressing Pancreatic Adenocarcinoma Cells Causes an Increase in the Antitumoral Activity
    Scientists investigated the cellular delivery ability and both in vitro and in vivo anti-tumoral activity of liposomes conjugated with two different low molecular weight hyaluronic acid (HA), the primary ligand of CD44, and containing a lipophilic gemcitabine pro-drug. By confocal microscopy and flow cytometry analyses, they demonstrated that the cellular uptake into a highly CD44-expressing pancreatic adenocarcinoma cell line is higher with HA-conjugated than non-conjugated liposomes. [Biochim Biophys Acta] Abstract

    Reduction in ATP Levels Triggers Immunoproteasome Activation by the 11S (PA28) Regulator during Early Antiviral Response Mediated by IFNβ in Mouse Pancreatic β-Cells
    Of special interest to immunoproteasome activation in β-cells are the effects of IFNβ, a type I IFN secreted by virus-infected cells and implicated in type I diabetes onset, compared to IFNγ, the classic immunoproteasome inducer secreted by cells of the immune system. By qPCR analysis, researchers showed that mouse insulinoma MIN6 cells and mouse islets accumulate the immune proteolytic β1i, β2i and β5i, and 11S mRNAs upon exposure to IFNβ or IFNγ. [PLoS One] Full Article

    Microenvironment Generated during EGFR Targeted Killing of Pancreatic Tumor Cells by ATC Inhibits Myeloid-Derived Suppressor Cells through COX2 and PGE2 Dependent Pathway
    Researchers investigated the mechanism(s) of bispecific antibody armed ATC mediated inhibition of myeloid-derived suppressor cells (MDSCs) in the presence or absence of Th1 microenvironment. They used 3D co-culture model of peripheral blood mononuclear cells with pancreatic cancer cells MiaPaCa-2 and gemcitabine resistant MiaPaCa-GR cells to generate MDSC in the presence or absence of Th1 cytokines and EGFRBi armed ATC. [J Transl Med] Abstract | Full Article

    New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells

    REVIEWS

    Prospects on Human Embryonic Stem Cell-Derived Pancreatic Progenitor Expansion
    Scientists discuss present approaches, as well as future alternatives, in the fields of basic and clinic research on β cell differentiation, derivation and transplantation. [Cell Res] Full Article

    Exploiting Inflammation for Therapeutic Gain in Pancreatic Cancer
    This review explores the pathways known to modulate inflammation at different stages of tumor development, drawing conclusions on their potential as therapeutic targets in pancreatic ductal adenocarcinoma. [Br J Cancer] Full Article

    From Pancreatic Islet Formation to Beta-Cell Regeneration
    The authors describe briefly the genetic program underlying mouse pancreas development and present new insights regarding β-cell regeneration. [Diabetes Res Clin Pract] Abstract

    INDUSTRY NEWS

    Levine Cancer Institute, UNC Charlotte Announce Innovative Pancreatic Cancer Research Partnership
    Carolina HealthCare System’s Levine Cancer Institute and University of North Carolina (UNC) Charlotte will enter into a joint project to advance translational and clinical research in the field of pancreatic cancer. The collaborative effort aims to foster more working relationships between physicians and scientists at both institutions by offering funding for innovative research ideas, submitted to and reviewed by a committee of their peers. [The University of North Carolina at Charlotte] Press Release

    Novo Nordisk Receives Complete Response Letter in the US for Tresiba® and Ryzodeg®

    Novo Nordisk announced that it received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Applications for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart). A Complete Response Letter is issued by the FDA, when the agency determines that an application cannot be approved in its current form. [Novo Nordisk A/S] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)
     
    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    National Health Service (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW StemCONN 2013: Realizing the Promise 
    April 3, 2013
    New Haven, United States

    Visit
    our events page to see a complete list of events in the pancreatic cell community.

    JOB OPPORTUNITIES

    Postdoctoral Researcher (The University of Texas Health Science Center at San Antonio)

    Postdoctoral Position – Diabetes Research (Lund University)

    Postdoctoral Position – Pancreatic Beta-Cell Dysfunction (Weill Cornell Medical College)

    Postdoctoral Position – Diabetes Research (Sanofi-Aventis Deutschland GmbH)

    Postdoctoral Position – Pancreas Development (INSERM)

    Postdoc Position – Beta Cell Signaling (The University of Southern Denmark)

    Postdoctoral Position (Skirball Institute / NYU Medical Center)

    PhD Studentship – Developmental Genes in Adult Pancreas Homeostasis & Energy Metabolism (Helmholtz Zentrum München)

    Research Position – Diabetes Research (Johns Hopkins University)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Pancreatic Cell News: Archives | Events | Contact Us